J. Godfroid

发表

Structure-activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A(2) inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2-alkylpiperazines.

C. Mounier, C. Dong, C. Redeuilh, 2001, European journal of medicinal chemistry.

Structure-activity relationships in platelet activating factor. 9. From PAF-antagonism to PLA2 inhibition.

C. Mounier, C. Binisti, E. Touboul, 1997, Journal of lipid mediators and cell signalling.

Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic series.

G. Dive, C. Redeuilh, A. Lamouri, 1997, Journal of lipid mediators and cell signalling.

Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines.

N. Blavet, G. Dive, A. Lamouri, 1997, Journal of lipid mediators and cell signalling.

SELECTIVE OXIDATION OF PRIMARY SILYL ETHERS AND ITS APPLICATION TO THE SYNTHESIS OF NATURAL PRODUCTS

B. Spur, J. Godfroid, M. Nomen, 1999 .

Potent antihyperglycaemic property of a new imidazoline derivative S‐22068 (PMS 847) in a rat model of NIDDM

B. Guardiola-Lemaitre, P. Renard, B. Pfeiffer, 1998, British journal of pharmacology.

Total synthesis of lipoxin A4 and lipoxin B4 from butadiene

B. Spur, J. Godfroid, Tak H. Lee, 2000 .

Endothelium-dependent vasorelaxation induced by Cn-acetal plasmalogens.

P. Braquet, C. Broquet, J. Godfroid, 1987, Prostaglandins, leukotrienes, and medicine.

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline.

G. Dive, P. Renard, B. Pfeiffer, 1999, Journal of medicinal chemistry.

Quantitative structure-activity relationships for N-[N',N'-disubstituted-amino)acetyl]arylamines for local anesthetic activity and acute toxicity.

F. Heymans, J. Godfroid, L. Le Thérizien, 1980, Journal of medicinal chemistry.

Platelet activating factor (PAF‐acether): total synthesis of 1‐O‐octadecyl 2‐O‐acetyl sn‐glycero‐3‐phosphoryl choline

C. Redeuilh, F. Heymans, J. Godfroid, 1980, FEBS letters.

Total synthesis of 12(R)-HETE, 12(S)-HETE, 2H2-12(R)-HETE and LTB4 from racemic glycidol via hydrolytic kinetic resolution

B. Spur, J. Godfroid, Tak H. Lee, 2001 .

Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs.

B. Vargaftig, M. Chignard, C. Broquet, 1986, European journal of pharmacology.

Structural analogs of platelet-activating factor (PAF-acether).

F. Heymans, J. Godfroid, J. Benveniste, 1981, Biochimie.

Conformational Properties of the PAF-Acether Receptor on Platelets Based on Structure—Activity Studies

P. Braquet, J. Godfroid, 1987 .

PAF-acether specific binding sites: 1. quantitative SAR study of PAF-acether isosteres

P. Braquet, J. Godfroid, 1986 .

PAF-acether specific binding sites: 2. Design of specific antagonists

P. Braquet, J. Godfroid, 1986 .

Synthesis and biological activity of some structural analogs of platelet-activating factor (PAF-acether)

J. Godfroid, J. Benveniste, J. Polonsky, 1981, Agents and Actions.

New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures.

F. Heymans, J. Godfroid, J. Benveniste, 1981, Biochimica et biophysica acta.

Structure-activity relationships in platelet-activating factor (PAF). 7. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors. Synthesis and PAF-antagonistic activity.

N. Blavet, G. Dive, C. Redeuilh, 1996, Journal of lipid mediators and cell signalling.

1H-and 13C-NMR studies of platelet-activating factor (PAF-acether) and analogs

F. Heymans, J. Godfroid, O. Convert, 1984 .

PAF receptor and “cache-oreilles” effect. Simple PAF antagonists

D. Hosford, P. Braquet, G. Dive, 1991, Lipids.

Total direct chemical synthesis and biological activities of human group IIA secretory phospholipase A2.

A. Romieu, B. Roques, C. Mounier, 2002, The Biochemical journal.

Stimulation of insulin release from the MIN6 cell line by a new imidazoline compound, S‐21663: evidence for the existence of a novel imidazoline site in β cells

D. Bataille, K. Peyrollier, J. Godfroid, 1997, British journal of pharmacology.

Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme.

C. Dong, C. Redeuilh, J. Huet, 2005, Bioorganic & medicinal chemistry.

Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats.

N. Morgan, P. Renard, B. Pfeiffer, 1999, European journal of pharmacology.

Preventive effects of two PAF-antagonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injury.

A. Lamouri, C. Pham-Huy, F. Heymans, 1997, Journal of lipid mediators and cell signalling.

QUANTITATIVE STRUCTURE‐ACTIVITY RELATIONSHIPS FOR DICOUMAROL ANTIVITAMINS K IN THE UNCOUPLING OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION

J. Godfroid, R. Labbe-Bois, C. Laruelle, 1975 .

Quantitative structure-activity relationships for dicoumarol antivitamins K in the uncoupling of mitochondrial oxidative phosphorylation.

J. Godfroid, C. Laruelle, 1975, Journal of medicinal chemistry.

Structure—Activity Relationships in Platelet‐Activating Factor (PAF). 11‐From PAF‐Antagonism to Phospholipase A2 Inhibition: Syntheses and Structure—Activity Relationships in 1‐Arylsulfamido‐2‐alkylpiperazines.

C. Mounier, C. Dong, C. Redeuilh, 2002 .

Total Synthesis of Leukotrienes from Butadiene

B. Spur, J. Godfroid, Tak H. Lee, 2000 .

Structure-activity relationships on adrenoceptors and imidazoline-preferring binding sites (I(1,2)-PBSs). Part 1: Weak intramolecular H-bond and conformational flexibility in a new I1-PBS-selective imidazoline analogue, trans1-(4',5'-dihydro-1'H-imidazol-2'-yl)methyl-2-hydroxyindane (PMS 952).

G. Dive, F. Heymans, J. Godfroid, 2000, Bioorganic & medicinal chemistry.

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .

G. Dive, P. Renard, B. Pfeiffer, 1997, Journal of medicinal chemistry.

An Efficient Asymmetric Synthesis of Prostaglandin E1

B. Spur, J. Godfroid, M. Nomen, 1999 .

4-Alkoxybenzamidines as new potent phospholipase A2 inhibitors.

C. Mounier, C. Binisti, F. Heymans, 1996, Biochemical pharmacology.

Structure-activity relationships in platelet-activating factor (PAF). 5. Synthesis and in vitro antagonistic activities of ketophosphonates.

C. Broquet, J. Haelters, J. Godfroid, 1991, Journal of lipid mediators.

Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.

C. Redeuilh, C. Broquet, F. Heymans, 1987, Journal of medicinal chemistry.

Synthesis of ether phospholipids.

C. Broquet, F. Heymans, J. Godfroid, 1986, Pharmacological research communications.

Alkyl analogs of diacylglycerol as activators of protein kinase C

M. Castagna, F. Heymans, J. Godfroid, 1987, FEBS letters.

Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.

P. Braquet, N. Blavet, G. Dive, 1993, Journal of medicinal chemistry.

A selective method for the preparation of aliphatic methyl esters in the presence of aromatic carboxylic acids

B. Spur, J. Godfroid, M. Nomen, 1998 .

Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.

D. Dormont, C. Dong, C. Redeuilh, 2000, Journal of medicinal chemistry.

Structure-activity relationships in platelet-activating factor (PAF). 8. Tetrahydrofuran derivatives as dual PAF antagonists and acetylcholinesterase inhibitors: anti-acetylcholinesterase activity and comparative SAR.

N. Blavet, J. Godfroid, L. Texier, 1996, Journal of lipid mediators and cell signalling.

Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s.

C. Mounier, C. Dong, A. Lamouri, 2005, European journal of medicinal chemistry.

Molecular Modeling, Design, and Synthesis of Less Lipophilic Derivatives of 3-(4-Tetradecyloxybenzyl)-4H-1,2,4-oxadiazol-5-one (PMS1062) Specific for Group II Enzyme†

N. Gresh, C. Dong, F. Chau, 2005 .

PMS-601, a New Platelet-Activating Factor Receptor Antagonist That Inhibits Human Immunodeficiency Virus Replication and Potentiates Zidovudine Activity in Macrophages

D. Dormont, A. Lamouri, F. Heymans, 2000, Antimicrobial Agents and Chemotherapy.

Macrophages Potentiates Zidovudine Activity in Immunodeficiency Virus Replication and Receptor Antagonist That Inhibits Human PMS-601 , a New Platelet-Activating Factor

A. Lamouri, F. Heymans, J. Godfroid, 2000 .

In vitro mechanism of action on insulin release of S‐22068, a new putative antidiabetic compound

F. Ashcroft, F. Gribble, J. Godfroid, 1999, British journal of pharmacology.

Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes.

P. Renard, B. Pfeiffer, A. Lamouri, 1996, The Journal of pharmacology and experimental therapeutics.

Structure-activity relationship in PAF-acether. 2. rac-1-O-Octadecyl-2-O-acetyl-3-O-[gamma-(dimethylamino)propyl]glycerol .

C. Broquet, F. Heymans, J. Godfroid, 1985, Journal of medicinal chemistry.

Handbook of PAF and PAF Antagonists

J. Godfroid, 1992 .

Effects of a new anorectic drug (PM 170) on development of gold thioglucose-induced obesity in mice.

F. Heymans, J. Godfroid, M. Apfelbaum, 1987, General pharmacology.

A new phospholipase A2 inhibitor, unrelated to substrate analogues: kinetic characterization of the inhibition of secretory phospholipases A2 by PMS 832.

C. Mounier, C. Binisti, E. Touboul, 1997, Journal of Lipid Mediators and Cell Signalling.

PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists.

P. Braquet, G. Dive, J. Lamotte‐Brasseur, 1989, Journal of lipid mediators.

Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.

C. Broquet, F. Heymans, J. Godfroid, 1988, Journal of medicinal chemistry.

A quantitative structure-activity approach to chemoreception: importance of lipophilic properties.

F. Heymans, J. Godfroid, F Heymans, 1977, Journal of theoretical biology.